NeuroSense Therapeutics (NRSNW) Expected to Announce Quarterly Earnings on Monday

NeuroSense Therapeutics (NASDAQ:NRSNW) will likely be posting its resultson Monday, June 22nd. Analysts expect NeuroSense Therapeutics to post earnings of ($0.0847) per share and revenue of $0.5140 million for the quarter.

NeuroSense Therapeutics Price Performance

NRSNW opened at $0.18 on Monday. NeuroSense Therapeutics has a one year low of $0.07 and a one year high of $1.00. The company’s 50 day simple moving average is $0.16 and its 200-day simple moving average is $0.24.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.